Fernandes J, et al. – The hospitalization costs of metastatic melanoma in France were comprehensively appraised from 2011 to 2013, from the perspective of the government payer. The hospitalization costs associated with metastatic melanoma exhibited significant increase with the progression of the disease. Therapeutic strategies slowing down disease progression would aid in reducing its costs. Nevertheless, they could exhibit prominent acquisition costs. This would entail organizational changes of resource allocation for its treatment in hospitals.